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Background: The aim of this study was to use a longitudinal computerised health care
dataset (The Health Improvement Network) to provide information on the overall
incidence of cancer, and on the incidence of organ-specific cancers, in people with
idiopathic pulmonary fibrosis (IPF) and sarcoidosis in comparison to the general population.
Methods: Incident cases of IPF and sarcoidosis were identified with up to four controls
matched by age, gender and general practice. Cancer incidence rates were compared
between cohorts using Cox regression and adjusting for age, gender and smoking habit.
Results: One thousand and sixty-four incident cases of IPF (mean age at diagnosis 71.5
years; 62.4% male) were identified. Overall, the incidence of cancer was increased in
people with IPF compared to the general population (rate ratio 1.51; 95% CI 1.20–1.90),
but this was largely due to a marked increase in the incidence of lung cancer (rate ratio
4.96; 95% CI 3.00–8.18). One thousand one hundred and fifty-three incident cases of
sarcoidosis (mean age at diagnosis 47.0 years; 47.2% male) were identified. There was an
overall increased incidence of cancer in sarcoidosis (rate ratio 1.65; 95% CI 1.22–2.24) and
this was largely explained by an increase in the incidence of skin cancers (rate ratio 1.86;
95% CI 1.11–3.11).
Conclusions: This study provides further evidence of a marked increase in the incidence of
lung cancer in people with IPF, but we found no increase in the risk of other cancers.
People with sarcoidosis did have an increase risk of skin cancers, but not cancers at other
sites.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
Medicine, Clinical Sciences Building, Nottingham City Hospital, Nottingham, NG5 1PB, England.
s.net (I. Le Jeune), jonathan.gribbin@ntlworld.com (J. Gribbin), joe.west@nottingham.ac.uk
k (C. Smith), p.cullinan@ic.ac.uk (P. Cullinan), Richard.Hubbard@nottingham.ac.uk (R. Hubbard).
ARTICLE IN PRESS
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK 2535Introduction rather than prevalent cases. Those with connective tissueThe possible association between idiopathic pulmonary
fibrosis (IPF) and lung cancer was first noted in a series of
cases described over 30 years ago.1 Three large epidemio-
logical studies have subsequently investigated this associa-
tion with conflicting results. The first study reported a
relative risk of lung cancer of 14.1 in patients with IPF
compared to the general population.2 These findings were
not supported by the second study, however, which used
death certificates to investigate the frequency of recording
of lung cancer for people with fibrosing alveolitis compared
to coal-workers pneumoconiosis and silicosis.3 A more
recent cohort study used computerised primary care data
from the UK and demonstrated an increase in the risk of lung
cancer in patients with IPF of a similar magnitude to that
seen by Turner-Warwick et al.2,4 No studies have examined
the incidence of cancer at other sites in patients with IPF.
Early studies of patients with sarcoidosis suggested a
possible association with malignancy, particularly lymphoma
and lung cancer.5–7 Two Danish studies have investigated the
incidence of cancer in hospital-based cohorts of people with
sarcoidosis, using national cancer statistics for the general
population as the comparator.8,9 Both found small increases
in cancer incidence in people with sarcoidosis which were
not significant at the 5% level. More recently, a larger study
has compared the incidence of cancer in a cohort of people
with sarcoidosis derived from the Swedish inpatient registry
to national data and found a small increase in the risk of
cancer overall, together with specific increases in stomach,
small intestine, large intestine and skin cancer and also
lymphoma and leukaemia.10 The main limitation of all of
these studies is that the comparator data are drawn from
national statistics and so no allowance can be made for
confounders acting at the individual level, such as smoking
habit.
The aims of this paper were to provide more accurate
information on the incidence of lung cancer in patients with
IPF, to perform a systematic examination of cancers at other
sites in patients with IPF and to study the putative
association between sarcoidosis and malignancy.Methods
The Health Improvement Network (THIN) is a longitudinal
primary care dataset, which includes diagnostic and
prescription data collected as part of routine primary care
in the UK.11 The version of THIN used in this study includes
information collected up to November 2004 by 255 primary
care centres. Each person in THIN has a start date, defined
as the later of their date of registration or practice date of
computerisation, and a stop date defined as the earliest of
date of death or last data collection.
For this study we analysed data from two patient cohorts,
one containing people with IPF and one with people with
sarcoidosis and two matched general population control
cohorts.
People were included in the IPF cohort if they had at least
one recorded IPF diagnosis and their first IPF diagnosis was
recorded at least 12 months after their start date at initial
diagnosis. This strategy was designed to capture incidentdiseases and under the age of 40 were excluded from the
dataset to increase the diagnostic specificity. A control
cohort consisting of up to four general population controls
per IPF patient, matched by age, gender and general
practice was selected. An index date, defined as the earliest
recorded diagnosis of IPF for the cases and the same date for
the matched controls, was assigned to each study partici-
pant. All of the controls were contributing data at the time
of the index data. For each case and control, we extracted
information on smoking habit throughout the data record
and diagnoses of cancer after the index date.
Similar methods were used to identify a cohort of people
with sarcoidosis and a matched control cohort, though for
these analyses no age restrictions were applied.
We extracted data on smoking habit for all study
participants and recoded these data as non/never, current
or ex-smokers or missing. Where data permitted, current
smokers were divided into groups who smoked o10, 10–19
and X20 per day. We estimated the association between
smoking habit and diagnoses of IPF or sarcoidosis in
comparison to general population controls using conditional
logistic regression.
In order to compare the incidence of cancer between
cases and controls, we initially calculated the crude cancer
rates, and then used multivariate Cox regression models to
compare cohorts and allow for the possible confounding
effects of age, gender and smoking habit. Initially time to
any malignancy was analysed, then the times to following
subsets of: any malignancy excluding non-melanomatous
skin cancer (NMSC), skin cancers, lung cancer, prostate
cancer (in men), gastrointestinal cancers, breast cancer (in
women), leukaemia, lymphoma, gynaecological cancers (in
women), ear, nose and throat (ENT) cancers, renal cancers
and liver cancers were explored individually. In the analyses
of cancer incidence the start of follow-up was defined as the
index date, and the finish date was either the date of a
cancer diagnosis or the date of last data collection,
whichever came first. Evidence of an effect modification
by age, gender and smoking habit was assessed by fitting
multiplicative interaction terms, and proportional hazard
assumptions were checked using a combination of the
diagnostic section within STATA (stsphtest in version 8,
STATA Corporation, Texas) and log–log plots. Likelihood ratio
tests were used for all hypothesis tests. STATA version 8 was
used for all of the statistical analyses and likelihood ratio
tests.
The study protocol was reviewed and approved by the
Nottingham Research Ethics Committee.Results
A total of 1064 incident cases of IPF were identified. The
mean age at diagnosis was 71.5 years (S.D. 10.6 years) and
62.4% were male. The total number of person-years of
follow-up after the diagnosis of IPF was 2598 years (mean
2.4 years). A total of 4238 matched controls (3.98 per case)
were identified. The mean age of the controls at their
matched diagnosis date was 71.5 years (S.D. 10.6 years) and
62.4% were male. The total follow-up time for the IPF
control cohort was 15,294 person-years (mean 3.6 years).
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I. Le Jeune et al.2536People with IPF were marginally more likely to be a current
or ex-smokers than controls but these effects were not
significant at the 5% level, and no dose–response relation-
ship was apparent (Table 1).
The absolute numbers of diagnoses for all cancers and
cancers at specific sites for people with IPF and their
matched controls are given in Table 2 along with rate per
10,000 person-years, and both age and gender, and age,
gender and smoking status adjusted rate ratios with 95%
confidence intervals. No further analysis was carried out in
the categories where no cases of cancer were found in
either the IPF cohort or their controls. During the period of
study follow-up, 93 people with IPF and 371 controls were
diagnosed with at least one malignancy. There was a small
but significant increase in ‘‘all cancers’’ when adjusted for
age, gender and smoking habit (rate ratio 1.51; 95%
confidence intervals 1.20–1.90). Our specific site analysis
demonstrated a marked increase in the incidence of lung
cancer in patients with IPF compared to the general
population (rate ratio 4.96; 95% confidence intervals
3.00–8.18), but no statistically significant increases at other
sites.
One thousand one hundred and fifty-three incident cases
of sarcoidosis were identified. Their mean age at diagnosis
was 47.0 years (S.D. 13.9 years) and 47.2% were male. The
total number of person-years of follow-up after the index
diagnosis of sarcoidosis was 6083 (mean 5.3 years). A total of
4610 controls (4.0 per case) were identified. The mean age
of the controls at their matched diagnosis date was 47.0
years (S.D. 13.9 years) and 47.2% were male. The total
follow-up time for the sarcoidosis control cohort was 23,746
person-years (mean 5.2 years). People with sarcoidosis were
less likely to be current smokers than their matched controls
(odds ratio of 0.53; 95% confidence intervals 0.45–0.63) and
the protective effect of smoking did seem to be dose-
related (Table 3).
The absolute numbers of diagnoses for all cancers and
cancers at specific sites for people with sarcoidosis and their
matched controls are given in Table 4 along with rate per
10,000 person-years, and both age and gender, and age,
gender and smoking status adjusted hazard ratios with 95%Table 1 Association between smoking habit and IPF.
Smoking status/
amount
Cases (n (%)) Controls (n (%
Smoking status
Non 398 (43%) 1670 (47%)
Current 284 (31%) 1043 (29%)
Ex 240 (26%) 858 (24%)
Missing 142 667
Total with smoking status data ¼ 4493 (84.7%)
Cigarettes per day
Non 398 (37.4%) 1670 (39.4%)
o10 50 (4.7%) 164 (3.9%)
10–19 50 (4.7%) 199 (4.7%)
X20 56 (5.3%) 217 (5.1%)
Number of current smokers with data on amount smoked ¼ 736confidence intervals. During the period of study follow-up,
58 people with sarcoidosis and 161 controls were diagnosed
with at least one malignancy. This produced a 53% relative
increase in risk among people with sarcoidosis (rate ratio of
1.53; 95% confidence interval 1.13–2.07) when adjusted for
age and gender. This effect increased further (rate ratio
1.65; 95% confidence interval 1.22–2.24) after adjusting for
smoking status. An increase of similar magnitude was seen
for skin cancers when adjusted for age, gender and smoking
status (rate ratio 1.86; 95% confidence interval 1.11–3.11).
The age, gender and smoking habit adjusted relative risk of
lymphoma showed the most marked increase (rate ratio
7.04; 95% confidence interval 1.54–32.1). None of the other
cancers at specific sites demonstrated a difference in
incidence in sarcoidosis at the 95% level.
We found no evidence that the proportional hazards
assumptions for our final models were incorrect.
Discussion
In a large cohort of people with IPF, we found a small
increase in cancer incidence overall compared to the
general population, largely accounted for by a marked
increase in the incidence of lung cancer. There was no
significant risk of cancers at other sites. In our cohort of
people with sarcoidosis we also found a small relative
increase in the incidence of cancer which due almost
entirely to an increase in the incidence of skin cancers.
Strengths and weaknesses of the study
The main strengths of our study are the large size of our
cohorts, the presence of an appropriate internal general
population control group, and the availability of data on an
individual basis to allow us to control for smoking habit. In
addition the duration of follow-up, though limited by poor
median survival in IPF, was sufficient to allow us to examine
reasonable absolute numbers of cancer diagnoses.
The main potential weakness of our study is the validity
of the IPF, sarcoidosis and cancer diagnoses. In general, the)) Odds ratio
(95% confidence interval)
p-Value for trend
1
1.17 (0.98–1.41)
1.21 (1.00–1.46)
–
1
1.31 (0.93–1.84) 0.712
1.08 (0.77–1.51)
1.11 (0.80–1.54)
(55.5%)
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Table 2 Diagnoses of cancer in incident IPF.
Condition and cohort Number of events Rate per 10,000
person-years
Rate ratio
(95% confidence interval)
Rate ratioy
(95% confidence interval)
All malignancies
Control 371 254 1.51 1.51
IPF 93 373 (1.20–1.90) (1.20–1.90)
All malignancies except NMSC
Control 300 203 1.57 1.58
IPF 79 311 (1.23–2.02) (1.23–2.03)
Skin cancers
Control 93 61.7 1.09 1.08
IPF 16 62.6 (0.64–1.85) (0.63–1.84)
Lung cancer
Control 35 22.9 4.99 4.96
IPF 29 112 (3.03–8.22) (3.00–8.18)
Prostate cancer
Control 47 52.2 1.08 1.09
IPF 8 54.4 (0.51–2.30) (0.51–2.32)
Gastrointestinal cancer
Control 47 30.9 0.84 0.86
IPF 6 23.1 (0.36–1.97) (0.37–2.03)
Breast cancer
Control 23 37.5 1.23 1.17
IPF 5 45.5 (0.47–3.26) (0.44–3.10)
Leukaemia
Control 10 6.54 0.63 0.63
IPF 1 3.85 (0.08–5.01) (0.08–5.00)
Lymphoma
Control 6 3.93 2.48 2.73
IPF 3 11.6 (0.62–9.97) (0.68–11.1)
Gynaecological cancers
Control 2 3.23 2.20 2.21
IPF 1 9.04 (0.20–24.3) (0.20–24.4)
ENT cancers
Control 5 3.27
IPF 0
Renal cancer
Control 2 1.31
IPF 0
Liver cancer
Control 1 0.65 5.07 8.25
IPF 1 3.85 (0.31–82.5) (0.48–141)
Crude rate ratio adjusted for age and gender.
yRate ratio adjusted for age, gender and smoking habit.
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK 2537validity of diagnoses in general practice datasets has been
found to be high for a wide spectrum of diagnoses.12
Furthermore, we have previously investigated the validity of
the IPF diagnoses in the UK General Practice Research
Database (GPRD),4 a database with similarities and overlap
with THIN, and found it to be high. Although the diagnoses ofIPF and sarcoidosis have not been specifically validated in
THIN, it is unlikely that this dataset differs markedly from
the GPRD or that a general practitioner would record these
relatively uncommon, specialist diagnoses without confir-
mation from a referral to secondary care. Evidence
supporting this comes from the demographics of the IPF
ARTICLE IN PRESS
Table 3 Effect of smoking on the incidence of sarcoidosis.
Smoking status/
amount
Cases (n (%)) Controls (n (%)) Odds ratio
(95% confidence interval)
p-Value for trend
Smoking status
Non 662 (65%) 1966 (54%) 1
Current 238 (23%) 1256 (34%) 0.53 (0.45–0.63)
Ex 124 (12%) 444 (12%) 0.82 (0.66–1.03)
Missing 129 944 –
Total with smoking status data ¼ 4690 (81.4%)
Cigarettes per day
Non 662 (57.4%) 1966 (42.6%) 1
o10 47 (4.1%) 201 (4.4%) 0.68 (0.49–0.95) 0.0001
10–19 36 (3.1%) 294 (6.4%) 0.35 (0.25–0.51)
X20 40 (3.5%) 332 (7.2%) 0.35 (0.25–0.49)
Number of current smokers with data on amount smoked ¼ 950 (63.6%)
I. Le Jeune et al.2538and sarcoid datasets that are similar to those published
previously.2–4,13–15 The validity of a range of cancer
diagnoses has previously been tested in general practice
datasets and been found to be high.17 Furthermore, the
incidence rates of organ-specific cancer diagnoses in our
control group are similar to those reported for UK cancer
registrations (http://www.statistics.gov.uk/STATBASE).
Smoking data were available for a high percentage of the
cases and controls in both datasets, and the proportion of
current smokers is consistent with data reported in UK
household survey data. The ex-smoker rate is lower than
expected,18 however, and this almost certainly reflects a
degree of misclassification of ex-smokers as non-smokers. In
a previous study using a computerised general practice
database we found a similar misclassification of ex-smokers
as non-smokers, but also found that within current smokers
the dose–response relationship between number of cigar-
ettes smoked per day and lung cancer risk was entirely as
expected suggesting that the data on cigarettes per day
have high validity.4 Currently available data on the effect of
cigarette smoking on the incidence of IPF are mixed. Two
studies show a small increased risk of IPF in ever-smokers
with odds ratios of 1.6,13,14 but, in common with a number
of other studies,4,19 we found no significant effect. The
marginal increase of about 20% in recorded diagnoses of IPF
in current and ex-smokers was of a similar magnitude to
those demonstrated in our previous large cohort study.4 Our
data also demonstrate that current smokers are half as likely
to have a recorded diagnosis of sarcoidosis; this effect is still
greater in those people smoking over 10 cigarettes per day.
The protective effect of smoking is similar to that seen in
other studies15,16 adding further validity to our diagnoses of
sarcoidosis, and providing evidence of a dose-related effect
for the first time.IPF
This study is one of the largest cohort studies of IPF in the
absence of connective tissue disease in the literature to
date. Analysis of these data provides further evidence that
the incidence of lung cancer in IPF is markedly increasedcompared to the general population and that this effect is
independent of smoking status. Increased ascertainment of
lung cancers during the diagnosis of and follow-up of people
with IPF might explain some of the increase we observed,
but given the large magnitude of the increase it seems likely
to us that this is entirely explained by ascertainment. The
mechanism by which IPF increases the risk of lung cancer is
unclear, and though this may relate to the presence of
fibrosis it is also possible that other exposures associated
with IPF, such as the use of immunosuppressive drugs, may
also have a role.
A previous study from our group using the GPRD showed a
similar association between IPF and lung cancer (smoking-
adjusted RR 8.25; 95% confidence intervals 4.70–11.48).4
That study followed similar methodology but did not
attempt to exclude prevalent cases or to restrict the
diagnosis of cancer to those made after the diagnosis of
IPF. Post hoc analysis of our data including all cases, incident
and prevalent, however, did not appreciably alter the
results.Sarcoidosis
This is the first large cohort study to compare the incidence
of cancer in people with sarcoidosis to individuals in the
general population and to allow for the impact of smoking
habit. Our rate ratio of 1.65 for all cancers is slightly greater
than both the two Danish studies which demonstrated trends
towards increased cancer incidence with rate ratios of 1.49
and 1.2,8 respectively, and the larger Swedish study which
found a significant rate ratio 1.3.10 This difference is
accounted for in part by controlling for smoking habit: as
people with sarcoidosis are less likely to smoke than the
general population and smoking is an important risk factor
for many cancers it is likely that the previous findings under-
estimated the true association between sarcoidosis and
cancer risk.
Our analysis of individual cancer types indicates that the
most dramatic increases are in lymphoma (rate ratio 7.08)
and the more common skin cancers (rate ratio 1.89).
Examination of the absolute differences in incidence rates
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Table 4 Diagnoses of cancer in incident sarcoidosis.
Condition and cohort Number of events Rate per 10,000
person-years
Rate ratio
(95% confidence interval)
Rate ratioy
(95% confidence interval)
All malignancies
Control 161 69.1 1.53 1.65
Sarcoidosis 58 98.6 (1.13–2.07) (1.22–2.24)
All malignancies except NMSC
Control 131 55.9 1.27 1.37
Sarcoidosis 40 67.2 (0.89–1.82) (0.96–1.96)
Skin cancers
Control 49 20.8 1.80 1.86
Sarcoidosis 21 35.0 (1.08–3.00) (1.11–3.11)
Lung cancer
Control 7 2.95 2.57 3.24
Sarcoidosis 4 6.58 (0.75–8.84) (0.94–11.2)
Prostate cancer
Control 9 8.11 0.98 1.00
Sarcoidosis 2 7.15 (0.21–4.56) (0.21–4.68)
Gastrointestinal cancer
Control 15 6.32 0.85 0.92
Sarcoidosis 3 4.94 (0.24–2.93) (0.26–3.22)
Breast cancer
Control 29 23.3 1.11 1.29
Sarcoidosis 8 24.7 (0.51–2.42) (0.59–2.85)
Leukaemia
Control 3 1.26
Sarcoidosis 0
Lymphoma
Control 3 1.26 5.34 7.04
Sarcoidosis 4 6.61 (1.19–23.9) (1.54–32.1)
Gynaecological cancers
Control 1 0.79
Sarcoidosis 0
ENT cancers
Control 3 1.26
Sarcoidosis 0
Renal cancer
Control 3 1.26
Sarcoidosis 0
Liver cancer
Control 1 0.42 3.78 2.88
Sarcoidosis 1 1.64 (0.24–60.6) (0.18–46.3)
Crude rate ratio adjusted for age and gender.
yRate ratio adjusted for age, gender and smoking habit.
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK 2539reveals that an increase in the diagnosis of skin cancers is
the most important component of this overall increase in
cancer incidence. We were concerned that this increase
might represent ascertainment bias due to the visibility of
skin lesions and the increased contact with medical
practitioners after a diagnosis of sarcoidosis; however, therewas no equivalent increase in skin cancers in the IPF cohort.
In addition, an increased incidence of skin cancers in
sarcoidosis has been reported previously.10 The increase in
lymphoma has also been demonstrated in early case series
of patients with sarcoidosis5–7 and the Askling cohort.10
The high rate ratio, however, results from small absolute
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I. Le Jeune et al.2540numbers and we were concerned that the effect could be
due to misdiagnosis. Examination of individual cases
revealed a time gap of 1.44–3.00 years between the
diagnosis of sarcoidosis and subsequent reporting of lym-
phoma which would be in keeping with the possibility of
misdiagnosis.
Summary
Our findings suggest that people with IPF have a markedly
increased risk of developing lung cancer. People with IPF
should be strongly encouraged to give up smoking and should
be offered smoking cessation advice and support as a matter
of urgency. Our findings also suggest that people with IPF
might represent a suitable population for lung cancer
screening. In general, our findings with regard to cancer in
people with sarcoidosis are reassuring although further
research is required to elucidate the association between
sarcoidosis and skin cancer.
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